Androgens in prostate cancer: A tale that never ends

被引：28
作者：
Hou, Zemin [1 ]
Huang, Shengsong [2 ]
Li, Zhenfei [1 ,2 ]
机构：
[1] Univ Chinese Acad Sci, Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci,Shanghai Inst Bio, 320 Yueyang Rd, Shanghai 200031, Peoples R China
[2] Tongji Univ, Tongji Hosp, Dept Urol, Sch Med, Shanghai 200065, Peoples R China
来源：
CANCER LETTERS | 2021年 / 516卷
基金：
中国国家自然科学基金; 国家重点研发计划;
关键词：
Steroidogenesis; Abiraterone resistance; Enzalutamide resistance; Bipolar androgen therapy; Androgen receptor; HUMAN 3-BETA-HYDROXYSTEROID DEHYDROGENASE; DNA-BINDING DOMAIN; ABIRATERONE ACETATE; DEPRIVATION THERAPY; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CYTOCHROME B(5); DOUBLE-BLIND; CASTRATION; RECEPTOR;
D O I：
10.1016/j.canlet.2021.04.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the nextgeneration androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.
引用
收藏
页码：1 / 12
页数：12
相关论文
共 138 条
[1]   Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes [J].
Aggarwal, Rahul ;
Zhang, Tian ;
Small, Eric J. ;
Armstrong, Andrew J. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (05) :719-726
[2]   HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer [J].
Almassi, Nima ;
Reichard, Chad ;
Li, Jianbo ;
Russell, Carly ;
Perry, Jaselle ;
Ryan, Charles J. ;
Friedlander, Terence ;
Sharifi, Nima .
JAMA ONCOLOGY, 2018, 4 (04) :554-557
[3]   Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities [J].
Alyamani, Mohammad ;
Li, Zhenfei ;
Berk, Michael ;
Li, Jianneng ;
Tang, Jingjie ;
Upadhyay, Sunil ;
Auchus, Richard J. ;
Sharifi, Nima .
CELL CHEMICAL BIOLOGY, 2017, 24 (07) :825-+
[4]   Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor [J].
Andersen, Raymond J. ;
Mawji, Nasrin R. ;
Wang, Jun ;
Wang, Gang ;
Haile, Simon ;
Myung, Jae-Kyung ;
Watt, Kate ;
Tam, Teresa ;
Yang, Yu Chi ;
Banuelos, Carmen A. ;
Williams, David E. ;
McEwan, Iain J. ;
Wang, Yuzhou ;
Sadar, Marianne D. .
CANCER CELL, 2010, 17 (06) :535-546
[5]   DELETION OF STEROID 5-ALPHA-REDUCTASE 2-GENE IN MALE PSEUDOHERMAPHRODITISM [J].
ANDERSSON, S ;
BERMAN, DM ;
JENKINS, EP ;
RUSSELL, DW .
NATURE, 1991, 354 (6349) :159-161
[6]   Effect of Dutasteride on the Risk of Prostate Cancer. [J].
Andriole, Gerald L. ;
Bostwick, David G. ;
Brawley, Otis W. ;
Gomella, Leonard G. ;
Marberger, Michael ;
Montorsi, Francesco ;
Pettaway, Curtis A. ;
Tammela, Teuvo L. ;
Teloken, Claudio ;
Tindall, Donald J. ;
Somerville, Matthew C. ;
Wilson, Timothy H. ;
Fowler, Ivy L. ;
Rittmaster, Roger S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) :1192-1202
[7]  
[Anonymous], 2020, Cancer Discov, V10, P1084, DOI 10.1158/2159-8290.CD-NB2020-054
[8]   AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Wang, Hao ;
Luber, Brandon ;
Nakazawa, Mary ;
Roeser, Jeffrey C. ;
Chen, Yan ;
Mohammad, Tabrez A. ;
Chen, Yidong ;
Fedor, Helen L. ;
Lotan, Tamara L. ;
Zheng, Qizhi ;
De Marzo, Angelo M. ;
Isaacs, John T. ;
Isaacs, William B. ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038
[9]   Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade [J].
Arora, Vivek K. ;
Schenkein, Emily ;
Murali, Rajmohan ;
Subudhi, Sumit K. ;
Wongvipat, John ;
Balbas, Minna D. ;
Shah, Neel ;
Cai, Ling ;
Efstathiou, Eleni ;
Logothetis, Chris ;
Zheng, Deyou ;
Sawyers, Charles L. .
CELL, 2013, 155 (06) :1309-1322
[10]   Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].
Attard, Gerhardt ;
Reid, Alison H. M. ;
Yap, Timothy A. ;
Raynaud, Florence ;
Dowsett, Mitch ;
Settatree, Sarah ;
Barrett, Mary ;
Parker, Christopher ;
Martins, Vanessa ;
Folkerd, Elizabeth ;
Clark, Jeremy ;
Cooper, Colin S. ;
Kaye, Stan B. ;
Dearnaley, David ;
Lee, Gloria ;
de Bono, Johann S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571
12345678910